Association of Hemoglobin A1c Levels With Use of Sulfonylureas, Dipeptidyl Peptidase 4 Inhibitors, and Thiazolidinediones in Patients With Type 2 Diabetes Treated With Metformin | Zendy

Rohit Vashisht | Zendy; Kenneth A. Jung | Zendy; Alejandro Schuler | Zendy; Juan M. Banda | Zendy; Rae Woong Park | Zendy; Sanghyung Jin | Zendy; Li Li | Zendy; Joel T. Dudley | Zendy; Kipp W. Johnson | Zendy; Mark Shervey | Zendy; Hua Xu | Zendy; Yonghui Wu | Zendy; Karthik Natrajan | Zendy; George Hripcsak | Zendy; Peng Jin | Zendy; Mui Van Zandt | Zendy; Anthony Reckard | Zendy; Christian Reich | Zendy; James Weaver | Zendy; Martijn J. Schuemie | Zendy; Patrick Ryan | Zendy; Alison Callahan | Zendy; Nigam H. Shah | Zendy

Open Access

Association of Hemoglobin A_1c Levels With Use of Sulfonylureas, Dipeptidyl Peptidase 4 Inhibitors, and Thiazolidinediones in Patients With Type 2 Diabetes Treated With Metformin

Author(s) -

Rohit Vashisht,

Kenneth A. Jung,

Alejandro Schuler,

Juan M. Banda,

Rae Woong Park,

Sanghyung Jin,

Li Li,

Joel T. Dudley,

Kipp W. Johnson,

Mark Shervey,

Hua Xu,

Yonghui Wu,

Karthik Natrajan,

George Hripcsak,

Peng Jin,

Mui Van Zandt,

Anthony Reckard,

Christian Reich,

James Weaver,

Martijn J. Schuemie,

Patrick Ryan,

Alison Callahan,

Nigam H. Shah

Publication year - 2018

Publication title -

jama network open

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.278

H-Index - 39

ISSN - 2574-3805

DOI - 10.1001/jamanetworkopen.2018.1755

Subject(s) - metformin , type 2 diabetes , dipeptidyl peptidase 4 inhibitor , medicine , hemoglobin , diabetes mellitus , dipeptidyl peptidase 4 , pharmacology , endocrinology

Key Points Question Can the effectiveness of second-line treatment of type 2 diabetes after initial therapy with metformin be characterized via an open collaborative research network? Findings In this analysis of data from more than 246 million patients in multiple cohorts, treatment with dipeptidyl peptidase 4 inhibitors compared with sulfonylureas and thiazolidinediones did not differ in reducing hemoglobin A 1c levels or hazard of kidney disorders. In a meta-analysis, sulfonylureas compared with dipeptidyl peptidase 4 inhibitors were associated with a small increased hazard of myocardial infarction and eye disorders in patients with type 2 diabetes. Meaning Large-scale characterization of the effectiveness of type 2 diabetes therapy across nations through an open collaborative research network aligns with the 2017 recommendation of the American Association of Clinical Endocrinologists and American College of Endocrinology in type 2 diabetes management recommending dipeptidyl peptidase 4 inhibitors over sulfonylureas in patients with diabetes for whom metformin was the first-line treatment.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research